Class of Stock [Axis]
Series A Junior [Member]
Preferred Stock Undesignated [Member]
Equity Components [Axis]
Common Stock [Member]
Preferred Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Treasury Stock, Common [Member]
AOCI Attributable to Parent [Member]
Parent [Member]
Noncontrolling Interest [Member]
Legal Entity [Axis]
Reddington Partners LLC [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Axis]
Stock Purchase Agreement [Member]
Scenario [Axis]
First Closing [Member]
Second Closing [Member]
Contribution Agreement [Member]
Business Combination [Axis]
Mag Mile Capital Inc [Member]
Orocidin A/S [Member]
Bio-Convert A/S [Member]
Related and Nonrelated Parties [Axis]
Award Type [Axis]
Restricted Stock [Member]
Directors Agreement [Member]
Title and Position [Axis]
Mr. Ritter [Member]
Messrs. Jensen [Member]
Investment, Name [Axis]
Alteral Therapeutics [Member]
Ownership [Axis]
Novi Thera [Member]
Antidilutive Securities [Axis]
Warrant [Member]
Share-Based Payment Arrangement, Option [Member]
Bio Convert [Member]
Consolidated Entities [Axis]
Subsidiary Issuer [Member]
Bio-Convert A/S [Member]
Subsequent Event Type [Axis]
Subsequent Event [Member]
GK Partners [Member]
Statistical Measurement [Axis]
Minimum [Member]
Maximum [Member]
Short Term Lease Agreement [Member]
GK Partners Aps [Member]
Mr. Bennett Yankowitz [Member]
Henrik Rouf [Member]
NP Bioinnovation A/S [Member]
Board of Directors Chairman [Member]
Director [Member]
Darlington Group LLC [Member]
Measurement Frequency [Axis]
Fair Value, Recurring [Member]
Fair Value Hierarchy and NAV [Axis]
Fair Value, Inputs, Level 1 [Member]
Fair Value, Inputs, Level 2 [Member]
Fair Value, Inputs, Level 3 [Member]
Private Investors [Member]
Board Of Directors [Member]
Incentive Stock Options [Member]
Performance Shares [Member]
Service Shares [Member]
Monte Carlo [Member]
Third Party [Member]
Income Tax Jurisdiction [Axis]
Income Tax Jurisdiction, Domestic Federal [Member]
Income Tax Jurisdiction, Foreign [Member]
Debt Instrument [Axis]
Two Demand Promissory Notes [Member]
Reddington [Member]
Additional Demand Promissory Note [Member]
Five Private Investors [Member]
Cover [Abstract]
Document Type
Amendment Flag
Amendment Description
Document Registration Statement
Document Annual Report
Document Quarterly Report
Document Transition Report
Document Shell Company Report
Document Shell Company Event Date
Document Period Start Date
Document Period End Date
Document Fiscal Period Focus
Document Fiscal Year Focus
Current Fiscal Year End Date
Entity File Number
Entity Registrant Name
Entity Central Index Key
Entity Primary SIC Number
Entity Tax Identification Number
Entity Incorporation, State or Country Code
Entity Address, Address Line One
Entity Address, Address Line Two
Entity Address, Address Line Three
Entity Address, City or Town
Entity Address, State or Province
Entity Address, Country
Entity Address, Postal Zip Code
Country Region
City Area Code
Local Phone Number
Extension
Written Communications
Soliciting Material
Pre-commencement Tender Offer
Pre-commencement Issuer Tender Offer
Title of 12(b) Security
No Trading Symbol Flag
Trading Symbol
Security Exchange Name
Title of 12(g) Security
Security Reporting Obligation
Annual Information Form
Audited Annual Financial Statements
Entity Well-known Seasoned Issuer
Entity Voluntary Filers
Entity Current Reporting Status
Entity Interactive Data Current
Entity Filer Category
Entity Small Business
Entity Emerging Growth Company
Elected Not To Use the Extended Transition Period
Document Accounting Standard
Other Reporting Standard Item Number
Entity Shell Company
Entity Public Float
Entity Bankruptcy Proceedings, Reporting Current
Entity Common Stock, Shares Outstanding
Documents Incorporated by Reference [Text Block]
ICFR Auditor Attestation Flag
Document Financial Statement Error Correction [Flag]
Document Financial Statement Restatement Recovery Analysis [Flag]
Auditor Firm ID
Auditor Opinion [Text Block]
Auditor Name
Auditor Location
Statement [Table]
Statement [Line Items]
ASSETS
Current assets:
Cash
Prepaid expenses and other current assets
Total current assets
In-process research and development
Property, plant, and equipment, net
Goodwill
Investment in Mag Mile Capital, Inc.
Other assets
Total assets
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable and accrued expenses
Note payable
Total current liabilities
Deferred tax liability
Total liabilities
Commitments and contingencies
Stockholders’ equity:
Preferred stock, value
Common Stock; $0.001 par value; 50,000,000 shares authorized; 19,128,896 and 17,252,502 shares issued and outstanding at March 31, 2026 and March 31, 2025, respectively
Treasury stock; 57,796 and 154 shares at cost at March 31, 2026 and March 31, 2025, respectively
Additional paid-in capital
Accumulated other comprehensive income
Accumulated deficit
Total equity attributed to the parent
Non-controlling interest
Total stockholders’ equity
Total liabilities and stockholders’ equity
Preferred stock, par value
Preferred stock, shares authorized
Preferred stock, shares Issued
Preferred stock, shares outstanding
Common stock, par value
Common stock, shares authorized
Common stock, shares issued
Common stock, shares outstanding
Treasury stock, shares
Income Statement [Abstract]
Revenue
Operating expenses:
Officer compensation
Professional fees
Consulting expense
General and administrative
Research and development
Total operating expenses
Loss from operations
Other (expense) income:
Interest expense
Change in fair value of warrant liability (related party)
Change in fair value of investment
Other expense
Total other (expense) income
Loss before provision for income taxes
Provision for income tax
Net loss
Net loss attributable to noncontrolling interests
Net loss attributable to Nordicus Partners Corporation
Other comprehensive income (loss):
Foreign currency translation adjustment
Comprehensive income (loss)
Net comprehensive income attributable to noncontrolling interests
Comprehensive income (loss) attributable to Nordicus Partners Corporation
Net loss per share attributable to Nordicus Partners Corporation - basic
Net loss per share attributable to Nordicus Partners Corporation - diluted
Weighted average common shares outstanding - basic
Weighted average common shares outstanding - diluted
Balance
Balance, shares
Common Stock issued in Orocidin business combination
Common Stock issued in Orocidin business combination, shares
Exercise of warrants
Exercise of warrants, shares
Cancellation of liability-classified warrants – Related party
Restricted common Stock issued for services
Common Stock issued for services, shares
Forgiveness of debt - related party
Vesting of restricted stock units - ESG Advisory Group
Vesting of restricted stock units - ESG Advisory Group, shares
Recognition of non-controlling interest in acquisition of Orocidin
Orocidin issuance of common stock in capital raise
Stock-based compensation
Common Stock issued in Bio-Convert business combination, net (See Note 10)
Common Stock issued in Bio-Convert business combination, net, shares
Common Stock issued to acquire remaining equity of Orocidin (See Note 10)
Common Stock issued to acquire remaining equity of Orocidin, shares
Net loss
Foreign currency translation adjustment
Issuance of restricted common stock
Issuance of restricted common stock, shares
Equity issued by subsidiary in connection with acquisition of intellectual property
Repurchase of shares
Repurchase of shares, shares
Balance
Balance, shares
Statement of Cash Flows [Abstract]
Cash flows from operating activities:
Adjustments to reconcile net loss to net cash used in operating activities:
Shares issued for services
Stock-based compensation
Change in fair value of warrant liability (related party)
Loss on sale of assets
Change in fair value of investment
Non-cash expense of IPR&D
Amortization of website costs
Changes in assets and liabilities:
Prepaid expenses and other current assets
Other assets
Accounts payable and accrued expenses
Foreign currency remeasurement
Net cash used in operating activities
Cash flows from investing activities:
Proceeds from sale of plant, property, and equipment
Purchase of plant, property, and equipment
Cash paid for website costs
Cash acquired in business combinations
Net cash (used in) provided by investing activities
Cash flows from financing activities:
Cash paid for stock issuance costs in business combinations
Repurchase of common stock
Proceeds from issuance of common stock
Proceeds from issuance of note payable
Proceeds from Orocidin issuance of common stock in capital raise
Proceeds from exercise of warrants
Net cash provided by financing activities
Net change in cash
Effect of exchange rate on cash
Cash at beginning of period
Cash at end of period
Supplemental disclosure of cash flow information:
Income taxes paid
Interest paid
Supplemental disclosures of non-cash information:
NoviThera equity issued for intellectual property
Common Stock issued for the acquisition of Bio-Convert
Common Stock issued for the acquisition of Orocidin
Cancellation of liability-classified warrants – related party
Forgiveness of debt - related party
Pay vs Performance Disclosure [Table]
Executive Category [Axis]
Individual [Axis]
Adjustment to Compensation [Axis]
Measure [Axis]
Pay vs Performance Disclosure, Table
Company Selected Measure Name
Named Executive Officers, Footnote
Peer Group Issuers, Footnote
Changed Peer Group, Footnote
PEO Total Compensation Amount
PEO Actually Paid Compensation Amount
Adjustment To PEO Compensation, Footnote
Non-PEO NEO Average Total Compensation Amount
Non-PEO NEO Average Compensation Actually Paid Amount
Adjustment to Non-PEO NEO Compensation Footnote
Equity Valuation Assumption Difference, Footnote
Compensation Actually Paid vs. Total Shareholder Return
Compensation Actually Paid vs. Net Income
Compensation Actually Paid vs. Company Selected Measure
Total Shareholder Return Vs Peer Group
Compensation Actually Paid vs. Other Measure
Tabular List, Table
Total Shareholder Return Amount
Peer Group Total Shareholder Return Amount
Net Income (Loss)
Company Selected Measure Amount
Other Performance Measure, Amount
Adjustment to Compensation, Amount
PEO Name
Name
Non-GAAP Measure Description
Additional 402(v) Disclosure
Pension Benefits Adjustments, Footnote
Equity Awards Adjustments, Footnote
Erroneously Awarded Compensation Recovery [Table]
Restatement Determination Date [Axis]
Restatement Determination Date
Aggregate Erroneous Compensation Amount
Erroneous Compensation Analysis
Stock Price or TSR Estimation Method
Outstanding Aggregate Erroneous Compensation Amount
Aggregate Erroneous Compensation Not Yet Determined
Name
Forgone Recovery due to Expense of Enforcement, Amount
Forgone Recovery due to Violation of Home Country Law, Amount
Forgone Recovery due to Disqualification of Tax Benefits, Amount
Forgone Recovery, Explanation of Impracticability
Name
Compensation Amount
Restatement does not require Recovery
Awards Close in Time to MNPI Disclosures [Table]
Award Timing MNPI Disclosure
Award Timing Method
Award Timing Predetermined
Award Timing MNPI Considered
Award Timing, How MNPI Considered
MNPI Disclosure Timed for Compensation Value
Awards Close in Time to MNPI Disclosures, Table
Name
Underlying Securities
Exercise Price
Fair Value as of Grant Date
Underlying Security Market Price Change
Insider Trading Arrangements [Line Items]
Material Terms of Trading Arrangement
Name
Title
Rule 10b5-1 Arrangement Adopted
Non-Rule 10b5-1 Arrangement Adopted
Adoption Date
Rule 10b5-1 Arrangement Terminated
Non-Rule 10b5-1 Arrangement Terminated
Termination Date
Expiration Date
Arrangement Duration
Aggregate Available
No insider trading flag
Insider Trading Policies and Procedures [Line Items]
Insider Trading Policies and Procedures Adopted
Insider Trading Policies and Procedures Not Adopted
Cybersecurity Risk Management, Strategy, and Governance [Abstract]
Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]
Cybersecurity Risk Management Processes Integrated [Flag]
Cybersecurity Risk Management Processes Integrated [Text Block]
Cybersecurity Risk Management Third Party Engaged [Flag]
Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]
Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]
Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]
Cybersecurity Risk Board of Directors Oversight [Text Block]
Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]
Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]
Cybersecurity Risk Role of Management [Text Block]
Cybersecurity Risk Management Positions or Committees Responsible [Flag]
Cybersecurity Risk Management Positions or Committees Responsible [Text Block]
Cybersecurity Risk Management Expertise of Management Responsible [Text Block]
Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]
Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]
Material Cybersecurity Incident [Abstract]
Material Cybersecurity Incident Nature [Text Block]
Material Cybersecurity Incident Scope [Text Block]
Material Cybersecurity Incident Timing [Text Block]
Material Cybersecurity Incident Material Impact or Reasonably Likely Material Impact [Text Block]
Material Cybersecurity Incident Information Not Available or Undetermined [Text Block]
Accounting Policies [Abstract]
ORGANIZATION AND DESCRIPTION OF BUSINESS
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Organization, Consolidation and Presentation of Financial Statements [Abstract]
GOING CONCERN
Investments, All Other Investments [Abstract]
INVESTMENTS
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENTS
Equity [Abstract]
PREFERRED STOCK
COMMON STOCK TRANSACTIONS
Share-Based Payment Arrangement [Abstract]
STOCK-BASED COMPENSATION
Intangible Asset, Goodwill and Other [Abstract]
GOODWILL AND INTANGIBLE ASSETS
Warrants
WARRANTS
Income Tax Disclosure [Abstract]
INCOME TAX
Debt Disclosure [Abstract]
NOTE PAYABLE
Segment Reporting [Abstract]
SEGMENT REPORTING
Subsequent Events [Abstract]
SUBSEQUENT EVENTS
Basis of Presentation
Reverse Stock Split
Use of Estimates
Concentration of Credit Risk
Cash and Cash Equivalents
Principles of Consolidation
Segment Information
Translation Adjustment
Comprehensive Income (Loss)
Research and Development Costs
Stock-based Compensation
Fair Value of Financial Instruments
Distinguishing Liabilities from Equity
Net Loss per Share
Business Combinations
Purchase Accounting Measurement Period Adjustments
Goodwill
Indefinite-lived Intangible Assets
Revenue Recognition
Non-controlling Interests
Risks and Uncertainties
Income Taxes
Recently Adopted Accounting Pronouncements
Recently Issued Accounting Pronouncements
SCHEDULE OF DEFERRED INCOME TAX ACTIVITY
SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE
Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
SCHEDULE OF STOCK OPTION
SCHEDULE OF FAIR VALUE OF STOCK OPTIONS
SCHEDULE OF GOODWILL
SCHEDULE OF IN-PROCESS RESEARCH AND DEVELOPMENT ACTIVITY
SCHEDULE OF WARRANT ACTIVITIES
SCHEDULE OF LOSS BEFORE PROVISION FOR INCOME TAXES
SCHEDULE OF RECONCILIATION OF TAXES ON INCOME
SCHEDULE OF RECONCILIATION ON EFFECTIVE TAX RATE
SCHEDULE OF COMPONENTS OF DEFERRED TAX ASSETS AND DEFERRED TAX LIABILITIES
OrganizationConsolidationAndPresentationOfFinancialStatementsTable [Table]
Number of shares issued
Outstanding shares percentage
Cash consideration for shares
Reverse stock split
Common stock owned
Ownership percentage acquired
Number of shares issued for acquisition
Number of shares issued
Annual cash retainer amount
Share based compensation arrangement by share based payment award options grants in period gross, shares
Share Price
Equity method investment ownership percentage
Acquired percentage
AccountingPoliciesTable [Table]
Cash equivalents
Dilutive shares
Increase in in-process research and development
Deferred tax liabilities, in-process research and development
Increase in total consideration paid
Goodwill impairment charges
Indefinite-lived intangible assets, impairment charges
Revenue recognized
Ownership percentage
Prepaid expenses and other current assets
Other assets
Accounts payable and accrued expenses
Balance as of March 31, 2025
Foreign currency translation adjustment
Balance as of March 31, 2026
Accumulated deficit
Number of restricted shares issued
Common stock par value
Shares issued price per share
Gross proceeds from issuance of restricted stock
Defined Benefit Plan [Table]
Defined Benefit Plan Disclosure [Line Items]
Stock issued during period, value
Common stock price per share
Investments
RelatedPartyTransactionsTable [Table]
Warrant to purchase common stock
Warrant, exercise price
Warrant expiration date
Number of unexercised warrant shares
Common stock issued on exercise of warrants
Common stock price per share
Proceeds from warrant exercises
Common stock issued on exercise of warrants
Proceeds from exercise of warrants
Warrant liability
Number of shares purchased
Gross proceeds
Incurred expenses
Issued for services
Legal fees
Due to related party
Officers compensation
Employment agreement term
Employment agreement expiration date
Ownership interest percentage
Advances on service fee
Research and development expense
Fair Value, Recurring and Nonrecurring [Table]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investment in Mag Mile Capital, Inc.
Assets
Accumulated Other Comprehensive Income (Loss) [Table]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Preferred stock, shares issued and redeemed
Preferred stock, voting rights
Preferred stock, liquidation value per share
Preferred stock, shares issued
Common stock par value
Number of shares issued
Share price
Net proceeds
Number of shares authorized to repurchased
Description nn share repurchase program
Number of shares repurchased
Number of stock options outstanding, beginning
Weighted average exercised price per options outstanding, beginning
Weighted average remaining contractual term
Aggregate intrinsic value outstanding beginning
Number of stock options, granted
Weighted average exercised price per options , Granted
Number of stock options outstanding, ending
Weighted average exercised price per options outstanding, ending
Aggregate intrinsic value outstanding ending
Number of stock option outstanding, exercisable
Weighted average exercise price per option exercisable and vested
Weighted average remaining contractual term exercisable and vested
Aggregate intrinsic value exercisable and vested
Number of stock option outstanding, vested and expected
Weighted average exercise price per option vested and expected
Weighted average remaining contractual term vested and expected
Aggregate intrinsic value vested and expected
Expected volatility
Expected dividend yield
Exercise price
Expected term (years)
Risk-free rate
Exercise price
Contractual term (years)
Volatility (annual)
Dividend yield (per share)
Common stock authorized for issuance
Number of stock options outstanding
Share based compensation expense
Unrecognized compensation cost
Number of awards issued
Fair value of awards issued
Weighted-average grant date fair value of options granted
Performance awards were vesting
Number of common stock issued for consulting services
Value of common stock issued for consulting services
Restructuring Cost [Table]
Restructuring Cost and Reserve [Line Items]
Balance as of March 31, 2025
Foreign currency translation adjustment
Balance as of March 31, 2026
Balance as of March 31, 2025
Foreign currency translation adjustment
Balance as of March 31, 2026
Voting interest percentage
Share price per share
Acquired intangible assets
Common shares acquired
Fair value of consideration transferred
ScheduleOfWarrantActivitiesTable [Table]
ScheduleOfWarrantActivitiesLineItem [Line Items]
Number of Warrants, Outstanding, Beginning balance
Weighted Average Exercise Price, Outstanding, Beginning balance
Weighted Average Remaining Contractual Term, Outstanding
Number of Warrants, Issued
Weighted Average Exercise Price, Issued
Number of Warrants, Expired/cancelled
Weighted Average Exercise Price, Expired/cancelled
Number of Warrants, Exercised
Weighted Average Exercise Price, Exercised
Number of Warrants, Outstanding, Ending balance
Weighted Average Exercise Price, Outstanding, Ending balance
WarrantsTable [Table]
WarrantsLineItem [Line Items]
Warrants outstanding, intrinsic value
Domestic
Foreign
Tax Jurisdiction of Domicile [Extensible Enumeration]
Federal tax benefit
Federal statutory tax rate
Foreign tax diffrential
Foreign tax diffrential
Temporary differences
Temporary differences
Temporary differences
Increase in valuation allowance
Total Income tax expense
Effective tax rate
Federal statutory tax rate
Foreign rate differential
Permanent differences
Deferred Tax Assets:
Stock-based compensation
Net operating loss carryforwards
Total gross deferred tax assets
Valuation allowance
Net deferred tax assets
Deferred Tax Liabilities:
In-process research and development intangible assets
Total deferred tax liabilities
Net deferred tax liability
Effective Income Tax Rate Reconciliation [Table]
Effective Income Tax Rate Reconciliation [Line Items]
Federal tax rate
Operating loss carry forwards
Change in total valuation allowance
Operating loss limitation
Deferred tax assets
Tax benefit
Income tax effect of foreign currency translation adjustments
Short-Term Debt [Table]
Short-Term Debt [Line Items]
Promissory notes face value
Interest rate percent
Principal amount due
Interest expenses
Subsequent Event [Table]
Subsequent Event [Line Items]
Restricted shares
Common stock, par value
Price per share
Gross proceeds
Promissory notes
Promissory notes
No insider trading flag.
In process research and development.
Series A Junior [Member]
Preferred Stock Undesignated [Member]
Consulting expense.
Adjustments to additional paid in forgiveness of debt related party.
Stock Issued during period value of remaining equity.
Stock issued during period shares of reamaining equity.
Non-cash expense of IPR&D.
Increase decrease in foreign currency remeasurement
Covitherae equity issued for intellectual property.
Commons stock issued for acquisition of bioconvert.
Forgiveness of debt related party.
Orocidin A/S [Member]
Percentage of outstanding common stock.
Annual cash retainer, amount.
Directors Agreement [Member]
Mr. Ritter [Member]
Messrs. Jensen [Member]
Alteral Therapeutics [Member]
Novi Thera [Member]
Bio-Convert A/S [Member]
Mag Mile Capital Inc [Member]
Contribution Agreement [Member]
Stock Purchase Agreement [Member]
Reddington Partners LLC [Member]
First Closing [Member]
Second Closing [Member]
Reverse Stock Split [Policy Text Block]
Distinguishing Liabilities from Equity [Policy Text Block]
Purchase Accounting Measurement Period Adjustments Policy [Policy Text Block]
Increase in process research and development.
Bio Convert [Member]
Deferred tax liabilities, in-process research and development.
Increase in total consideration paid.
Bio-Convert A/S [Member]
Non controlling interests [Policy Text Block]
Risk and uncertainty [Policy Text Block]
Recently Issued Accounting Pronouncements [Policy Text Block]
GK Partners [Member]
Stock issued during period shares exercise of warrants.
Mr. Bennett Yankowitz [Member]
Henrik Rouf [Member]
Employment agreement term.
Employment agreement expiration date.
NP Bioinnovation A/S [Member]
Darlington Group LLC [Member]
Preferred stock, shares issued and redeemed
Stock issued during period shares exercises of warrants.
Private Investors [Member]
Board Of Directors [Member]
Description on repurchase program.
Incentive Stock Options [Member]
Service Shares [Member]
Monte Carlo [Member]
Share based compensation arrangement of share based payment award fair value assumptions exercise price description.
Third Party [Member]
Schedule of In-Process Research and Development Activity [Table Text Block]
Gain loss on research and development foreign currency translation adjustment.
Warrants [Text Block]
Share based compensation arrangement of share based payment award non option equity instruments outstanding weighted average remaining contractual terms.
Share based compensation arrangement of share based payment award non option equity instruments outstanding weighted average exercise price.
Share based compensation arrangement of share based payment award non option equity instruments granted weighted average exercise price.
Share based compensation arrangement of share based payment award non option equity instruments forfeitures and expirations weighted average exercise price.
Share based compensation arrangement of share based payment award non option equity instruments exercised weighted average exercise price.
Schedule Of Loss Before Provision For Income Taxes [Table Text Block]
Income tax reconciliation temporary diffrences.
Effective income tax rate reconciliation permanent differences.
Schedule Of Deferred Tax Assets And Liabilities Due To Temporary Differences [Table Text Block]
Deferred tax assets stock based compensation.
Two Demand Promissory Notes [Member]
Reddington [Member]
Additional Demand Promissory Note [Member]
Shares issued for services.
Other comprehensive income attributable to noncontrolling interests.
Cancellation of liability classified warrants related party.
Short Term Lease Agreement [Member]
GK Partners Aps [Member]
Five Private Investors [Member]
Bio-Convert A/S [Member] [Default Label]
Assets, Current
Assets
Liabilities, Current
Liabilities
Treasury Stock, Value
Equity, Attributable to Parent
Equity, Including Portion Attributable to Noncontrolling Interest
Liabilities and Equity
Operating Expenses
Operating Income (Loss)
Interest Expense, Nonoperating
Other Nonoperating Expense
Nonoperating Income (Expense)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest
Comprehensive Income (Loss), Net of Tax, Attributable to Parent
Other Comprehensive Income (Loss), Tax, Portion Attributable to Noncontrolling Interest
Shares, Outstanding
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent
Stock Repurchased During Period, Value
Share-Based Payment Arrangement, Noncash Expense
Gain (Loss) on Disposition of Assets
Increase (Decrease) in Prepaid Expense and Other Assets
Increase (Decrease) in Other Operating Assets
Increase (Decrease) in Accounts Payable and Accrued Liabilities
Increase decrease in foreign currency remeasurement
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation
Payments to Acquire Property, Plant, and Equipment
Payments for Software
Cash Provided by (Used in) Investing Activity, Including Discontinued Operation
Payments of Merger Related Costs, Financing Activities
Payments for Repurchase of Common Stock
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Excluding Exchange Rate Effect, Including Discontinued Operation
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation
ForgivenessOfDebtRelatedParty
Forgone Recovery, Individual Name
Outstanding Recovery, Individual Name
Awards Close in Time to MNPI Disclosures, Individual Name
Trading Arrangement, Individual Name
Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]
Prepaid Expense
Other Assets
Accounts Payable and Accrued Liabilities
StockIssuedDuringPeriodSharesExerciseOfWarrants
Proceeds from Issuance of Warrants
Investments, Fair Value Disclosure
Assets, Fair Value Disclosure
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value
ShareBasedCompensationArrangementOfShareBasedPaymentAwardFairValueAssumptionsExercisePriceDescription
Goodwill, Foreign Currency Translation, Gain (Loss)
GainLossOnResearchAndDevelopmentForeignCurrencyTranslationAdjustment
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice
Effective Income Tax Rate Reconciliation, Percent
DeferredTaxAssetsStockBasedCompensation
Deferred Tax Assets, Gross
Deferred Tax Assets, Valuation Allowance
Deferred Tax Assets, Net
Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs
Deferred Tax Liabilities, Gross
Deferred Tax Liabilities, Net
Debt Instrument, Interest Rate During Period